Trastuzumab deruxtecan was recommended in 20 cases with HER2-positive or HER2-low expression profiles, and enfortumab vedotin in 10 patients with advanced bladder cancer expressing NECTIN-4. This evidence concerns the gene ERBB2 and urinary bladder cancer.